Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Inclusion Criteria: * Patients must have histologically or cytologically confirmed malignant neoplasms (not including hematological malignancies and brain tumors) untreated or previously treated requiring further treatment; patients in Arm L (pembrolizumab), Arm M (nivolumab), and Arms N, O, P (nivolumab and ipilimumab) that have Food and Drug Administration (FDA)-approved indications for nivolumab, ipilimumab, and pembrolizumab do not have to fail first line nivolumab, ipilimumab, or pembrolizumab, and these patients may be treatment naïve if they have disease where pembrolizumab or nivolumab are FDA approved for the first-line setting * For all arms except Arm L (pembrolizumab), Arm M (nivolumab), and Arms N, O, P (nivolumab and ipilimumab) patients must have failed prior standard curative chemotherapy for their disease; subjects must have failed, be intolerant to, or be ineligible for any potentially curative approved treatment, irrespective of line of therapy * Patients must have measurable disease (Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1) * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * The patient must be recovered from a prior major surgery; the major surgery must be performed at least 4 weeks prior to consent date * Platelets \>= 125 x 10\^9/L (For Arm L pembrolizumab, Arm M nivolumab and Arms N, O, P \[nivolumab and ipilimumab\] and expansion cohorts for all arms, platelets \>= 100 x 10\^9/L) * Hemoglobin \>= 10 g/dL (For A…